72 Participants Needed

Soquelitinib for Eczema

Recruiting at 17 trial locations
LT
GL
Overseen ByGabriel Luciano

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a new drug called Soquelitinib to help people with severe skin problems. It targets those with moderate to severe Atopic Dermatitis and works by blocking a protein that causes inflammation.

Will I have to stop taking my current medications?

Yes, you may need to stop certain medications. The trial requires that you have not taken oral prednisone or similar drugs within 2 weeks before starting, and other immunosuppressive medications within 4 weeks before starting.

Who Is on the Research Team?

SM

Suresh Mahabhashyam, MD

Principal Investigator

Corvus Pharmaceuticals, Inc.

Are You a Good Fit for This Trial?

Adults over 18 with moderate to severe atopic dermatitis (eczema) who haven't had success with certain topical or systemic therapies can join. Participants must use contraception and women of childbearing potential must follow specific contraceptive guidance.

Inclusion Criteria

My skin condition has been confirmed as atopic dermatitis by a dermatologist.
My skin condition is moderate to severe, covering more than 10% of my body.
My skin condition didn't improve with certain creams or pills.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive soquelitinib or placebo tablets orally at specified dose levels for 28 days

4 weeks
Daily administration

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Soquelitinib
Trial Overview The trial is testing the safety, tolerability, and initial effectiveness of a drug called Soquelitinib compared to a placebo in adults with moderate to severe atopic dermatitis.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Soquelitinib Dose Escalation and Dose ExpansionExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Corvus Pharmaceuticals, Inc.

Lead Sponsor

Trials
9
Recruited
1,100+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security